VRX

5 Pharmaceutical and Biotech Stocks to Consider for July

By Chris Lau, InvestorPlace Contributor
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.

Valeant Pharmaceuticals Intl Inc Shares Sink on Psoriasis Treatment Rejection by FDA

By William White, InvestorPlace Writer
Valeant Pharmaceuticals (VRX) stock took a hit on Monday after the U.S. Food and Drug Administration rejected its psoriasis treatment.

Can Sprout Pharma’s Latest Revival Really Boost VRX Stock?

By Chris Lau, InvestorPlace Contributor
Sprout Pharma is about to revive the libido pill, Addyi. With the same leadership but autonomy from Valeant Pharma, Sprout could turn the drug into a success story.

Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play

By Chris Lau, InvestorPlace Contributor
Teva Pharmaceuticals is quietly moving higher on the stock market for good reason: worries over pricing and the impact of competition in generics is getting clearer. Teva stock is a great long-term bet.

Valeant Pharmaceuticals Intl Inc Has New Name But Same Problems

By Dana Blankenhorn, InvestorPlace Contributor
Valeant has put its scandals into the past and will change its name to Bausch, but it still has debt worth three times annual sales.

FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

By Karl Utermohlen, InvestorPlace Writer
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.

Wednesday’s Vital Data: Valeant Pharmaceuticals Intl Inc (VRX), Walt Disney Co (DIS) and Citigroup Inc (C)

By Joseph Hargett, InvestorPlace Contributor
Valeant (VRX) and Disney (DIS) options volume jumped on earnings while Citigroup (C) spikes as ValueAct takes a $1.2 billion stake.

4 Top Stock Trades for Wednesday Morning

By Bret Kenwell, InvestorPlace Contributor
Stocks had trouble finding direction on Tuesday, partly due to the Iran deal and the U.S. However, we're still looking for top stock trades going forward.

Valeant Pharmatceutical’s Debt Won’t Be Fooled by a Name Change

By Dana Blankenhorn, InvestorPlace Contributor
Valeant will soon become Bausch Health, but it will retain the debt it incurred on the way to its 2015 scandal.

10 ‘Toxic’ Stocks Investors Will Dump Next

By Vince Martin, InvestorPlace Contributor
These 10 stocks could be on the firing line soon, particularly if results disappoint or the broad market turns south.

It’s Time to Shop Shopify Inc Stock Now!

By Chris Tyler, InvestorPlace Contributor
If history rhymes, there’s sufficient supports to buy into Shopify stock today with a bull call spread.

3 Sell-Rated Drug Stocks Investors Should Avoid for Now

By
Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies....

5 Big Biotech Stocks to Buy Under $10

By Aaron Levitt, InvestorPlace Contributor
Small biotech stocks can pack a wallop. Here are five biotech stocks that have prospects bigger than their share prices.

How Valeant Pharmaceuticals Intl Inc Can Give You a 750% Return

By Chris Tyler, InvestorPlace Contributor
Improving bottom-lines off and on the price chart in Valeant stock build the case for an out-of-the-money bull call spread. Here's what you should do with VRX.

Intangibles Hold the Key to Valeant Pharmaceuticals Intl Inc Stock

By Will Healy, InvestorPlace Contributor
Valeant stock plunged on lower guidance, but Valeant is paying down debt and releasing new products which could help VRX recover.

5 Biotech Stocks to Sell Amid the Latest Slaughter

By Anthony Mirhaydari, InvestorPlace Market Strategist
These five biotech stocks are being hit particularly hard right now. Here's what investors should know about each of these stocks to sell.

Valeant Pharmaceuticals Intl Inc Stock Tumbles on Q4 Revenue Miss

By William White, InvestorPlace Writer
Valeant Pharmaceuticals (VRX) stock took a hit today following the release of its earnings report for the fourth quarter of 2017.

Valeant Pharmaceuticals International (VRX) a Buy on Solid Quant Score

By Portfolio Grader
Valeant Pharmaceuticals International Inc (NYSE:VRX) is one of the 657 companies in the GICS Health Technology sector, and a constituent of the 96 company Pharmaceuticals: Other GICS industry group within this sector. VRX's market value is $7.5 billion which places it in the top 10% of its industry group. Portfolio Grader's current ranking for VRX puts it 20 among the 96 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 160 among the 657 companies in the sector, and number 1,087 in the nearly 5,000 company Portfolio Grader universe.

Valeant Pharmaceuticals Intl Inc Stock Rides High as More Good News Awaits

By Chris Lau, InvestorPlace Contributor
VRX stock has soared in recent months as investors expect Valeant to continue improving its business in 2018.
Load More